Literature DB >> 19552926

Comparison study of amyloid PET and voxel-based morphometry analysis in mild cognitive impairment and Alzheimer's disease.

Masaaki Waragai1, Nobuyuki Okamura, Katsutoshi Furukawa, Manabu Tashiro, Shozo Furumoto, Yoshihito Funaki, Motohisa Kato, Ren Iwata, Kazuhiko Yanai, Yukitsuka Kudo, Hiroyuki Arai.   

Abstract

Two techniques employed for the early diagnosis of dementia are the imaging of amyloid-beta protein using positron emission tomography (PET) and voxel-based morphometry analysis of MRI (VBM-MRI). The purpose of this study was to evaluate the clinical utility of amyloid PET and VBM-MRI for the early diagnosis and tracking of the severity of Alzheimer's disease (AD). The neuritic plaque burden and gray matter losses were evaluated using [11C]BF-227-PET and VBM-MRI in 12 healthy controls, 13 subjects with mild cognitive impairment (MCI), including 6 who converted to AD and 7 who did not convert, and 15 AD patients. The AD patients and the MCI converters exhibited a neocortical retention of BF-227 and parahippocampal gray matter loss shown by VBM-MRI. The MCI converters were more clearly distinguished from the MCI non-converters in BF-227-PET than VBM-MRI. The combined sample of the MCI converters and AD patients showed a significant correlation of MMSE scores with the global gray matter loss, but not with the BF-227 retention. These findings suggest that amyloid PET using [11C]BF-227 is better suited for the prediction of conversion from MCI to AD, while VBM-MRI appears to be better suited for tracking the severity of dementia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19552926     DOI: 10.1016/j.jns.2009.06.005

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  16 in total

1.  Obstructive sleep apnea and longitudinal Alzheimer's disease biomarker changes.

Authors:  Omonigho M Bubu; Elizabeth Pirraglia; Andreia G Andrade; Ram A Sharma; Sandra Gimenez-Badia; Ogie Q Umasabor-Bubu; Megan M Hogan; Amanda M Shim; Fahad Mukhtar; Nidhi Sharma; Alfred K Mbah; Azizi A Seixas; Korey Kam; Ferdinand Zizi; Amy R Borenstein; James A Mortimer; Kevin E Kip; David Morgan; Ivana Rosenzweig; Indu Ayappa; David M Rapoport; Girardin Jean-Louis; Andrew W Varga; Ricardo S Osorio
Journal:  Sleep       Date:  2019-06-11       Impact factor: 5.849

Review 2.  The use of PET in Alzheimer disease.

Authors:  Agneta Nordberg; Juha O Rinne; Ahmadul Kadir; Bengt Långström
Journal:  Nat Rev Neurol       Date:  2010-02       Impact factor: 42.937

Review 3.  Obstructive Sleep Apnea and Its Treatment in Aging: Effects on Alzheimer's disease Biomarkers, Cognition, Brain Structure and Neurophysiology.

Authors:  Anna E Mullins; Korey Kam; Ankit Parekh; Omonigho M Bubu; Ricardo S Osorio; Andrew W Varga
Journal:  Neurobiol Dis       Date:  2020-08-27       Impact factor: 5.996

4.  In vivo detection of prion amyloid plaques using [(11)C]BF-227 PET.

Authors:  Nobuyuki Okamura; Yusei Shiga; Shozo Furumoto; Manabu Tashiro; Yoshio Tsuboi; Katsutoshi Furukawa; Kazuhiko Yanai; Ren Iwata; Hiroyuki Arai; Yukitsuka Kudo; Yasuhito Itoyama; Katsumi Doh-ura
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-12-17       Impact factor: 9.236

5.  A 18F-labeled BF-227 derivative as a potential radioligand for imaging dense amyloid plaques by positron emission tomography.

Authors:  Shozo Furumoto; Nobuyuki Okamura; Katsutoshi Furukawa; Manabu Tashiro; Yoichi Ishikawa; Kentaro Sugi; Naoki Tomita; Masaaki Waragai; Ryuichi Harada; Tetsuro Tago; Ren Iwata; Kazuhiko Yanai; Hiroyuki Arai; Yukitsuka Kudo
Journal:  Mol Imaging Biol       Date:  2013-08       Impact factor: 3.488

6.  Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment.

Authors:  V Camus; P Payoux; L Barré; B Desgranges; T Voisin; C Tauber; R La Joie; M Tafani; C Hommet; G Chételat; K Mondon; V de La Sayette; J P Cottier; E Beaufils; M J Ribeiro; V Gissot; E Vierron; J Vercouillie; B Vellas; F Eustache; D Guilloteau
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-01-18       Impact factor: 9.236

7.  Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease.

Authors:  Clifford R Jack; Heather J Wiste; Prashanthi Vemuri; Stephen D Weigand; Matthew L Senjem; Guang Zeng; Matt A Bernstein; Jeffrey L Gunter; Vernon S Pankratz; Paul S Aisen; Michael W Weiner; Ronald C Petersen; Leslie M Shaw; John Q Trojanowski; David S Knopman
Journal:  Brain       Date:  2010-10-08       Impact factor: 13.501

8.  A Toxic Conformer of Aβ42 with a Turn at 22-23 is a Novel Therapeutic Target for Alzheimer's Disease.

Authors:  Naotaka Izuo; Chihiro Kasahara; Kazuma Murakami; Toshiaki Kume; Masahiro Maeda; Kazuhiro Irie; Koutaro Yokote; Takahiko Shimizu
Journal:  Sci Rep       Date:  2017-09-18       Impact factor: 4.379

9.  Structural MRI and Amyloid PET Imaging for Prediction of Conversion to Alzheimer's Disease in Patients with Mild Cognitive Impairment: A Meta-Analysis.

Authors:  Eun Hyun Seo; Woon Yeong Park; Il Han Choo
Journal:  Psychiatry Investig       Date:  2017-03-06       Impact factor: 2.505

Review 10.  A survey of FDG- and amyloid-PET imaging in dementia and GRADE analysis.

Authors:  Daniela Perani; Perani Daniela; Orazio Schillaci; Schillaci Orazio; Alessandro Padovani; Padovani Alessandro; Flavio Mariano Nobili; Nobili Flavio Mariano; Leonardo Iaccarino; Iaccarino Leonardo; Pasquale Anthony Della Rosa; Della Rosa Pasquale Anthony; Giovanni Frisoni; Frisoni Giovanni; Carlo Caltagirone; Caltagirone Carlo
Journal:  Biomed Res Int       Date:  2014-03-19       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.